AstraZeneca drug lowers high BP in late-stage study; shares rise
The drug met the main and secondary goals of the study at two dosages, with a statistically significant and clinically meaningful reduction in systolic blood pressure at 12 weeks when given with standard treatment, and compared with placebo, AstraZeneca said.
The company added baxdrostat to its roster after it acquired CinCor Pharma in 2023 as part of its efforts to build out its pipeline of heart and kidney disease treatments.
AstraZeneca shares rose 2% to 106.60 pounds per share, and were among top percentage gainers on the blue-chip FTSE 100 (.FTSE), opens new tab index in early trading.
The drug works by targeting and suppressing the hormone aldosterone, which is responsible for increasing blood pressure and causing risk of heart and kidney diseases.
The drug is currently also being investigated as a standalone therapy for hypertension, and as part of a combination therapy for chronic kidney disease and the prevention of heart failure in high-risk patients with hypertension.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
4 minutes ago
- The Independent
The ‘concerning' impact of AI on health workers
A new study suggests that regular use of artificial intelligence could potentially 'deskill' health workers, a finding described as 'concerning' given AI 's rapid adoption in healthcare. The research focused on endoscopists performing colonoscopies to detect precancerous growths (adenomas) in the bowel. The study, conducted in Poland, analysed 1,442 colonoscopies and found a 6 per cent lower rate of polyp detection when endoscopists worked without AI after its introduction. This is believed to be the first study to indicate a negative impact of regular AI use on healthcare professionals' ability to complete a patient-relevant task in medicine. Academics are calling for urgent further research into AI's impact on health professionals' skills across various medical fields to understand and mitigate potential problems.
BBC News
5 minutes ago
- BBC News
In pictures: Gloucestershire Uni staff move into former Debenhams
University of Gloucestershire staff have begun moving into the former Debenhams building in Gloucester city new City Campus cost almost £75 million and will be a base for 1,200 students and staff, with the public also able to use some new campus will host education, psychology and social work students and will also be home to a new arts, health and wellbeing centre - run in partnership with the NHS - and a new public move marks the completion of work on the ground and first floors as part of phase one of the overall project. Dr Katerina Kantartzis, lead for the arts, health and wellbeing centre said it was an "exciting collaboration" with the NHS that would place greater emphasis on "social proscribing and preventative health". The new campus was partly paid for by the NHS and Gloucestershire Council in addition to grant and levelling up funding, with the remaining cost borne by the university. Clare Marchant, vice chancellor of the university, said the campus was "unique" in combining teaching, research and community spaces, adding that she hopes the new wellbeing space will help to identify and resolve issues faced by the "overburdened" NHS. The university bought the former department store in 2021 and it now contains lecture and seminar rooms, casual work spaces and research laboratories with virtual reality capabilities. Gloucestershire County Council leader Jeremy Hilton said the new campus would be at the "heart" of a "vibrant, sustainable and economically thriving" city centre, which will also include The Forum and the Greyfriars Quarter. Earlier plans for the campus included spaces fit for 4,000 students and staff. But during construction, the decision was made to invest in the university's Cheltenham campus and the nearby Golden Valley development, leaving the new campus with extra space. Some areas in the former Debenhams store are still under construction.
The Sun
5 minutes ago
- The Sun
CocaCola recalls popular fizzy drink over safety fears as shoppers urged ‘do not consume' & return to shops immediately
A POPULAR Coca-Cola product has been urgently recalled over health concerns. Shoppers have been urged to avoid consuming the product and return it to stores immediately. Appletiser has been pulled from shelves due to the soft drink containing "an elevated level of chlorate". In a statement on its website, the supermarket giant said: "Sainsbury's have been made aware that Appletiser are recalling the above products as they may contain an elevated level of chlorate. "We are asking customers that have purchased the above products not to consume them and to return them to their nearest Sainsbury's store, where they will receive a full refund. "For any further information please contact 0800 227711. "No other products have been affected by this issue. Appletiser would like to apologise for any inconvenience caused."
